Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Clinical Trials Directive

    - PMLiVE

    EMA reaffirms guidance on paracetamol use during pregnancy

    The guidance follows recent US comments about a possible link to autism

    - PMLiVE

    Johnson & Johnson seeks first EMA approval for icotrokinra for plaque psoriasis

    Icotrokinra is a first-in-class, once-daily tablet for moderate-to-severe plaque psoriasis

    - PMLiVE

    EMA orphan drug designation given to ReAlta for graft-versus-host disease therapy

    This follows preliminary results from the company's ongoing phase 2 trial

    - PMLiVE

    Organon/Henlius announce EMA validation for Perjeta biosimilar HLX11

    The reference medicine holds approvals for multiple HER2-positive breast cancer indications

    Biogen Idec building

    Biogen’s higher dose spinal muscular atrophy regimen accepted for review by EMA/FDA

    The neuromuscular disease affects approximately one in every 10,000 babies worldwide

    - PMLiVE

    Pfizer/BioNTech’s KP.2-adapted COVID-19 vaccine receives CHMP recommendation

    The updated vaccine was shown to generate an improved response against currently circulating variants

    tijana being interviewed

    Envision Analogue – An Introduction

    Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive...

    Genesis Research Group

    - PMLiVE

    AstraZeneca’s Tagrisso combination receives CHMP recommendation for advanced lung cancer

    More than 450,000 people are diagnosed with lung cancer every year in Europe

    - PMLiVE

    Pfizer’s one-time haemophilia B therapy Durveqtix receives CHMP recommendation

    More than 38,000 people worldwide are currently affected by the inherited bleeding disorder

    - PMLiVE

    CHMP recommends use of Moderna’s Omicron BA.1 booster in children in the EU

    The company is also evaluating the use of the vaccine in children aged from six months

    - PMLiVE

    Sanofi/ Regeneron’s Dupixent recommended by CHMP to treat eosinophilic oesophagitis

    Patients in a phase 3 trial experienced improvements in their ability to swallow after four weeks

    Trust and transparency in Pharma & healthcare: impact of the COVID-19 pandemic

    While it is obvious that trust in life science and healthcare companies is suboptimal, exactly how to improve the public’s trust is unclear...

    Impetus Digital

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links